K
Ken Op de Beeck
Researcher at University of Antwerp
Publications - 52
Citations - 1577
Ken Op de Beeck is an academic researcher from University of Antwerp. The author has contributed to research in topics: Cancer & DNA methylation. The author has an hindex of 23, co-authored 43 publications receiving 1183 citations. Previous affiliations of Ken Op de Beeck include Erasmus University Rotterdam.
Papers
More filters
Journal ArticleDOI
Apoptosis in acquired and genetic hearing impairment: The programmed death of the hair cell
TL;DR: The contribution of apoptosis in the pathology of both acquired and genetic hearing impairment is reviewed, suggesting that several mutations in apoptosis genes were identified as the cause of monogenic hearing impairment and that these genes constitute a new functional class within the hearing loss field.
Journal ArticleDOI
The DFNA5 gene, responsible for hearing loss and involved in cancer, encodes a novel apoptosis-inducing protein.
Ken Op de Beeck,Guy Van Camp,Sofie Thys,Nathalie Cools,Isabelle Callebaut,Karen Vrijens,Luc Van Nassauw,Viggo Van Tendeloo,Jean-Pierre Timmermans,Lut Van Laer +9 more
TL;DR: It is demonstrated that DFNA5 is composed of two domains, separated by a hinge region, which induces apoptosis when transfected in HEK293T cells, and the second region masks and probably regulates this apoptosis inducing capability.
Journal ArticleDOI
Whole exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1
Timon Vandamme,Marc Peeters,Fadime Dogan,Patrick Pauwels,Elvire Van Assche,Matthias Beyens,Geert Mortier,Geert Vandeweyer,Wouter W. de Herder,Guy Van Camp,Leo J. Hofland,Ken Op de Beeck +11 more
TL;DR: The first whole-exome profile of the BON-1 and QGP-1 cell lines is presented, to the authors' knowledge, and homozygous mutations in TP53 with possible loss of function were identified in both cell lines.
Journal ArticleDOI
Pharmacological Levels of Withaferin A (Withania somnifera) Trigger Clinically Relevant Anticancer Effects Specific to Triple Negative Breast Cancer Cells
Katarzyna Szarc vel Szic,Ken Op de Beeck,Dariusz Ratman,An Wouters,Ilse M. Beck,Ken Declerck,Karen Heyninck,Erik Fransen,Marc Bracke,Karolien De Bosscher,Filip Lardon,Guy Van Camp,Wim Vanden Berghe +12 more
TL;DR: Taking into account that sub-cytotoxic concentrations of WA target multiple metastatic effectors in therapy-resistant triple negative breast cancer, WA-based therapeutic strategies targeting the uPA pathway hold promise for further (pre)clinical development to defeat aggressive metastatic breast cancer.
Journal ArticleDOI
Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer.
Lieselot Croes,Matthias Beyens,Erik Fransen,Joe Ibrahim,Wim Vanden Berghe,Arvid Suls,Marc Peeters,Patrick Pauwels,Guy Van Camp,Ken Op de Beeck +9 more
TL;DR: It is concluded that DFNA5 methylation shows strong potential as detection and prognostic biomarker for breast cancer and that estrogen receptor state is associated with DFNA 5 methylation and expression.